← Back to Search

Mitochondrial Targeted Antioxidant

MitoQ for Frail Older Adults (Mito-Frail Trial)

Phase 2
Waitlist Available
Led By Oh Sung Kwon, PhD
Research Sponsored by UConn Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 visits : baseline, 12 weeks (mitoq or placebo), 8 weeks washout, 12 weeks (mitoq or placebo)
Awards & highlights

Mito-Frail Trial Summary

This trial examines the effects of MitoQ supplementation on vascular, physical & cognitive function in older adults, to see if it can improve health & cognitive abilities. #clinicaltrial

Who is the study for?
This trial is for men and women aged 65-80 who are experiencing frailty or mild cognitive issues, specifically those with slow walking speeds or mild memory problems. Participants must be in good heart health without taking any medications that affect blood pressure or metabolism.Check my eligibility
What is being tested?
The Mito-Frail Trial is testing if a supplement called MitoQ can improve blood vessel function, reduce oxidative stress, and enhance physical movement and thinking skills in older adults who are physically or cognitively frail.See study design
What are the potential side effects?
Potential side effects of MitoQ aren't detailed here, but like any supplement, it could cause digestive discomfort, allergic reactions, or interact with other medications. The placebo capsule should have no active effects.

Mito-Frail Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am not on medication for heart health or blood pressure.

Mito-Frail Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 visits : baseline, 12 weeks (mitoq or placebo), 8 weeks washout, 12 weeks (mitoq or placebo)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 visits : baseline, 12 weeks (mitoq or placebo), 8 weeks washout, 12 weeks (mitoq or placebo) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Cerebrovascular Function
Change in NIH Tool Box Composite
Change in Vascular Endothelial Function
+2 more
Secondary outcome measures
Change in Mitochondrial Function measured in peripheral blood mononuclear cells (PBMCs)
Change in Oxidative Stress measured in peripheral blood mononuclear cells (PBMCs) by O2flux in pmol/second/cell numbers

Mito-Frail Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MitoQ capsuleExperimental Treatment1 Intervention
Capsules containing mitoquinone mesylate (MitoQ, 5 mg/capsule) totaling 20 mg taken every day for 12 weeks.
Group II: Placebo capsulePlacebo Group1 Intervention
Gelatin capsules
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mitoquinone Mesylate
2022
N/A
~30

Find a Location

Who is running the clinical trial?

University of ConnecticutOTHER
184 Previous Clinical Trials
158,233 Total Patients Enrolled
1 Trials studying Aging
90 Patients Enrolled for Aging
UConn HealthLead Sponsor
211 Previous Clinical Trials
60,561 Total Patients Enrolled
3 Trials studying Aging
132 Patients Enrolled for Aging
National Institute on Aging (NIA)NIH
1,675 Previous Clinical Trials
28,020,825 Total Patients Enrolled
160 Trials studying Aging
75,947 Patients Enrolled for Aging

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age limitation for this experiment extend past 35 years old?

"According to the trial's conditions, only patients aged between 65 and 80 are eligible for enrolment. There is a large pool of 37 trials targeting participants below 18 years old and 942 clinical studies focusing on those above retirement age."

Answered by AI

Is this medical research still enrolling participants?

"As it is indicated on clinicaltrials.gov, the trial which was initially posted on September 28th of 2023 and last updated a few weeks ago is no longer looking for participants. However, there are 999 other studies actively recruiting at this time."

Answered by AI

What potential risks could arise from ingesting MitoQ capsules?

"Our experts at Power rate MitoQ capsule's safety as a 2 on the 1-3 scale, given that this is Phase 2 trial with only early data confirming its security but no evidence for efficacy."

Answered by AI

What prerequisites must be met for a person to enter this research project?

"This investigation is seeking 60 elderly individuals aged 65-80 with frailty. To be considered, potential participants must have a gait speed of 0.4m/s over a 4m walk and/or evidence of mild cognitive impairment."

Answered by AI

Who else is applying?

What site did they apply to?
UConn Health
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Oh Sung Kwon 2024. "The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06027554.
~40 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top